objeCtives: In the US, more than half of patients with idiopathic pulmonary fibrosis (IPF) are covered by Medicare; yet published data on the economic burden that IPF imposes to this largest US payer are limited. The objective of this study was to compare health care resource utilization (HRU) and costs between Medicare beneficiaries with IPF and matched non-IPF controls. Methods: Administrative claims from a 5% random sample of Medicare beneficiaries (aged 65+) from years 2000 to 2011 were analyzed. Incident IPF patients were identified based on ICD9-CM diagnosis codes, with at least one year enrollment before (pre-index) and after (post-index) the first diagnosis (index date). Up to 5 beneficiaries without IPF were matched to each IPF patient, based on age, gender, race, and region. Annual HRU and medical costs (excluding outpatient drug costs) during the pre-index and post-index periods were compared between IPF patients and the matched controls and univariate descriptive analyses were performed to compare the differences. Results: A total of 7,855 IPF patients were matched to 38,856 controls. During pre-index period, IPF patients had 2-3 folds higher risk of COPD, asthma and lung infections, 80% higher risk of hospitalization (28.8% vs. 15.8%), and higher total medical costs ($10,124 vs. $5,888) than matched controls (all p< 0.05). During post-index period, IPF patients had a higher risk of hospitalization (48.7% vs. 20.8%) and all other types of HRU with the total medical costs $11,955 higher than controls ($20,887 vs. $8,932 ) (all p< 0.05). Inpatient care accounted for 50% of total medical costs of IPF patients in both pre-index and post-index periods. ConClusions: In the US, IPF patients aged 65 or older had a greater burden of comorbidity and incurred more HRU and medical costs than matched controls. Multidisciplinary team based approach and effective therapies are needed given the high unmet needs. 491, 492, 496) were identified using the U. S. national Medicare claims dataset from 01JAN2009 to 31DEC2011. The first diagnosis date was defined as the index date. A comparator group was created by identifying patients without a COPD diagnosis but of similar age, region, gender, index year and baseline Charlson Comorbidity Index scores. The index date for the comparator group was randomly chosen to reduce selection bias. One-year pre-and post-index continuous health plan enrollment was required for both groups. A 1: 1 propensity score matching was used to compare follow-up health care costs and utilizations between the COPD and comparison cohorts, adjusted for baseline demographic and clinical characteristics. Results: A total of 422,024 patients were identified for the COPD and compari- objeCtives: This study aimed to evaluate the economic burden of hospitalized pneumonia and its associated costs in the Brazilian Private Health System. Methods: An administrative claims database containing over 18 million lives was used to identify hospitalized pneumonia episodes, in all ages, between Oct/2010 and Dec/2013. Pneumonia episodes were identified using ICD-10 codes of A40.3, B95.3, G00.1, J13, J15, J15.0, J15.3, J15.4, J15.8, J15.9, J18, J18.0, J18.9, J20.2, P23.3. Pneumonia costs included were taxes and exchange, medicines, materials, medicinal gases, food, medical fees, exams, procedures and personal hygiene. The costs represent a total in the evaluated period for all causes and considering the total patients identified, average cost was calculated. Results: A total of 16,227 pneumonia patients were identified with a total of 17,781 hospitalizations, representing an average of 1.1 hospitalizations per pneumonia patient in all ages. The aggregate costs for all inpatient treatment were BRL202,687,872.71 representing a total of 130,406 hospital days across the pneumonia patients. The average days for hospitalization per patient is 7.5 days. The average expenditure for the health insurance provider represents BRL12,490.78 per patient or BRL11,399.13, when evaluating per hospitalization. This translates to an average daily expenditure of BRL1,704.06 per patient or BRL1,555.13 per hospitalization. ConClusions: Costs related to pneumonia hospitalization are high and represents a large impact to the total budget spends in the private health care system. Given the significant economic burden associated with pneumonia, there is a need to better implement prevention strategies such as flu and pneumococcal vaccinations and smoking cessation. objeCtives: To compare the expected costs and outcomes associated with the novel once-daily fixed-dose combination (FDC) of inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) fluticasone furoate/vilanterol (FF/VI) against those expected with currently available FDC options, fluticasone propionate/salmeterol (FP/S), budesonide/formoterol (BUD/F) and beclometasone dipropionate/formoterol (BD/F), for asthma treatment in Slovenia. Methods: We developed a Markov model based on the results of seminal study GOAL (Gaining Optimal Asthma Control) that takes into account the complexity of asthma treatment and particularly accompanying dose titration. Using available clinical evidence, we assumed that the clinical efficacy and incidence of adverse events associated with a all four FDCs were similar. We compared FF/VI with other FDCs of ICS/LABA from the Slovenian payers' perspective at the price levels determined by international reference pricing as of April 2014. We followed a cohort of 12,300 asthma patients over the time horizon of 3 years with costs and outcoumes discounted at 3.5% per annum. Results: Model analysis showed that the expected three-year costs of FF/VI were lower than those of FP/S, BUD/F and BD/F by 13%, 40%, and 32%, respectively. The costs of treatment with FF/VI were lower than all other FDCs of ICS/LABA for patients who were previously treated with low/medium doses of ICSs (≤ 500 mg equivalent dose of BD) or high-doses of ICSs (> 500 mg and ≤ 1000 mg equivalent dose of BD). Budget impact analysis that was based on the current ICS/LABA market and projected market shares of FF/VI, FP/S, and BUD/F revealed that introduction of FF/VI could save the national Sick Fund € 863,000 over the first three years of use. ConClusions: Results of our model indicate that the introduction of the new once-daily FDC ICS/ LABA FF/VI could reduce the costs of asthma treatment in Slovenia over the first three years after introduction. objeCtives: To compare expected costs and health outcomes of the novel fixeddose combination (FDC) of inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) fluticasone furoate/vilanterol (FF/VI) with currently available FDC options, fluticasone propionate/salmeterol (FP/S) and budesonide/formoterol (BUD/F), for chronic obstructive pulmonary disease (COPD) treatment in Slovenia. Methods: We developed a population-level Markov model based on the results of seminal TORCH (Towards a Revolution in COPD Health) study that accounts for disease progression of COPD and particularly the effects of changes in lung function and exacerbations. Using available clinical evidence, we assumed that all FDCs of ICS/ LABA were clinically equivalent. We compared FF/VI with two other FDCs of ICS/ LABA from the payers' perspective at the Slovenian price levels determined by international reference pricing as of April 2014. We followed a cohort of 8,100 Slovenian COPD patients for 20 years, with costs and outcomes discounted at 3.5% per annum. Results: The life expectancy predicted by the model was 8.74 years with 2.76 years spent in moderate COPD, 2.55 years in severe COPD, and 3.43 in very severe COPD. Model analysis showed that the expected three-year survival of the cohort was 91% and that the expected corresponding costs of FF/VI (€ 1.021 per patient) were lower than those of FP/S (€ 1.535 per patient; +33% vs. FF/VI) and BUD/F (€ 1.260 per patient; +19% vs. FF/VI). Expected costs of maintenance, moderate exacerbations, severe exacerbations, and pneumonia were, for all treatment choices,
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